

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2017 OS

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A30; B7, B37; Cw6, Cw7; DR15, DR-; DQ6, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
				13	13	12	13	35	35	35	35	33	33	34	33	
				0	0	6	5	0	0	3	2	0	0	34	31	
				13	13	6	8	35	35	32	33	33	33	0	2	
				2	2	3	2	3	3	3	3	6	6	5	6	
				0.0%	0.0%	50.0%	38.5%	0.0%	0.0%	8.6%	5.7%	0.0%	0.0%	100.0%	93.9%	
				100.0%	100.0%	50.0%	61.5%	100.0%	100.0%	91.4%	94.3%	100.0%	100.0%	0.0%	6.1%	
Consensus				Negative	Negative	Not Assessed	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
HLA Antibody Specificity (Defined By CDC)				DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
112	YES			NT	NT	NT	NT									Low cell viability
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
116		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
119	YES			Negative	Negative	Positive	Positive									
120		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
128	YES			Negative	Negative	Negative	Negative									
133		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
143		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative			
145		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Very low number of B-cells
154		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
157		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
169		YES	YES					Negative	Negative	Negative	Negative	NT	NT	Positive	Positive	
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
193	YES	YES	YES	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
194		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Equivocal	
195		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
209	YES		YES	Negative	Negative	Positive	Positive					NT	NT	NT	NT	
216	YES			Negative	Negative	Negative	Negative									
223		YES	YES					Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	
227		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
229	YES															
232	YES			Negative	Negative	Positive	Negative									
235	YES			Negative	Negative	Positive	Negative									
238	YES	YES	YES	Negative	Negative	Equivocal	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
239	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Viability of negative controls were found highly positive. Samples can not be finalized.
245	YES	YES	YES	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
252	YES	YES	YES	Negative	Negative	Negative	Negative					Negative	Negative	Positive	Positive	
259	YES															
260		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
268		YES	YES					Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
292		YES	YES					Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
293		YES	YES					Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
321		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2017 OS

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					-	-	-	-	-	-	-	-			
112	NT	NT	NT	NT									65		
114					1	1	1	1	1	1	8	6			
116					1	1	1	1	1	1	8	2-6	95	85	
119	1	1	2	2									90		
120					1	1	1	1	1	1	8	8	99	99	
128	1	1	1	1									98		
133					2	2	2	2	2	2	8	8	90	80	80
139	1	1	1	1	1	1	1	1	1	1	8	8	85	85	85
143					1	1	1	1					93		
145					-	-	-	-	Equivocal	Equivocal	Equivocal	Equivocal	100	100	
147	1	1	2	1	1	1	1	1	1	1	8	6	100	100	90
154					-	-	-	-	-	-	6	6			
157					1	1	1	1	1	1	4	1	90		
159					1	1	1	1	1	1	8	8		99	90
162					-	-	-	-	-	-	6	2/4		100	100
163					1	1	1	1	1	1	8	8		80	80
169					1	1	1	1	NT	NT	8	8		97	97
181					1	1	1	1	1/2	1/2	8	8		100	100
186					0	0	0	0	0	0	8	6		99	99
189	1	1	1	1									95		
190					5	5	5	5	5	5	100	95	95	95	95
193	-	-	+	+	-	-	-	-	-	-	++++	++++	95	99	95
194					-	-	-	-	-	-	-	Equivocal			
195					2	2	2	2	2	2	6	6		80	70
197					-	-	-	-	-	-	Strong	Weak		90	90
204					1	1	1	1	1	1	8	8		95	90
206					1	1	1	1	1	1	8	8		100	60
209	1	1	2	2					NT	NT	NT	NT			
216	2	1	1	1									95		
223					1	1	4	1	1	1	8	8		95	95
227					-	-	-	-	-	-	8	-		98	98
229															
232	-	-	4+	-									80		
235	1	1	4	1									85		
238	1	1	2	4	1	1	1	1	1	1	8	6	98	98	60
239	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	40	40	40
245	1	1	2	2	1	1	1	1	1	1	8	8	100	100	100
252	1	1	1	1					1	1	6-8	4-6	85		70
259															
260					NT	NT	NT	NT	NT	NT	NT	NT		30	30
268					1	1	2	2	1	1	8	6		92	86
284					1	1	1	1	1	1	8	8		98	98
292					1	1	1	1	1	1	8	6		85	50
293					0	0	2+	2+	0	0	8+	8+		70	40
294					0	0	0	0	0	0	8	8		100	95
297					1	1	1	1	1	1	8	8		80	80
321					1	1	1	1	1	1	8	6		98	92
351															

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2017 OS

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A30; B7, B37; Cw6, Cw7; DR15, DR-, DQ6, DQ-

	Summary of Results											
	PBL				T-Cells				B-Cells			
Total tested	12	12	11	12	32	32	32	32	32	32	33	31
Positive	0	0	3	0	0	0	1	0	0	0	31	11
Negative	12	12	8	12	32	32	31	32	32	32	2	20
NT/Equivocal	1	1	2	1	2	2	2	2	4	4	3	5
% Positive	0.0%	0.0%	27.3%	0.0%	0.0%	0.0%	3.1%	0.0%	0.0%	0.0%	93.9%	35.5%
% Negative	100.0%	100.0%	72.7%	100.0%	100.0%	100.0%	96.9%	100.0%	100.0%	100.0%	6.1%	64.5%
Consensus	Negative	Negative	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Not Assessed
HLA Antibody Specificity (Defined By CDC)	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2

Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments		
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4			
101		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Low cell viability
112	YES			NT	NT	NT	NT											
114		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
116		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
119	YES									Negative	Negative	Negative	Negative					
120		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
133		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
139	YES		YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
143		YES								Negative	Negative	Negative	Negative					
147	YES		YES							Negative	Negative	Negative	Negative					
157		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
159		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
162		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
163		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
169		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
181		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
186		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
189	YES									Negative	Negative	Negative	Negative					
190		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
193	YES		YES							Negative	Negative	Positive	Negative					
194		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Equivocal	
195		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
197		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
204		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
206		YES	YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
209	YES		YES							Negative	Negative	Positive	Negative			NT	NT	
216	YES									Negative	Negative	Negative	Negative					
227		YES	YES							Negative	Negative	Negative	Negative					
229	YES																	
235	YES									Negative	Negative	Positive	Negative					
238	YES	YES	YES							Negative	Negative	Equivocal	Negative					
245	YES	YES	YES							Negative	Negative	Negative	Negative					
252	YES		YES							Negative	Negative	Negative	Negative					
260		YES	YES							NT	NT	NT	NT					
262	YES		YES							Negative	Negative	Negative	Negative					
268		YES	YES							Negative	Negative	Negative	Negative					
284		YES	YES							Negative	Negative	Negative	Negative					
292		YES	YES							Negative	Negative	Negative	Negative					
293		YES	YES							Negative	Negative	Negative	Negative					
294		YES	YES							Negative	Negative	Positive	Negative					
297		YES	YES							Negative	Negative	Negative	Negative					
321		YES	YES							Negative	Negative	Negative	Negative					
351		YES	YES							NT	NT	NT	NT					

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2017 OS

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					-	-	-	-	-	-	-	-			
112	NT	NT	NT	NT									65		
114					1	1	1	1	1	1	8	6			
116					1	1	1	1	1	1	6-8	1-2		95	85
119	1	1	1	1									90		
120					1	1	1	1	1	1	8	1		99	99
133					2	2	2	2	2	2	8	8	90	80	80
139	1	1	1	1	1	1	1	1	1	1	8	4	85	85	85
143					1	1	1	1						93	
147	1	1	2	1	1	1	1	1	1	1	8	6	100	100	90
157									1	1	1	1	90		
159					1	1	1	1	1	1	8	8		99	90
162					-	-	-	-	-	-	6	-		100	100
163					1	1	1	1	1	1	8	1		80	80
169					1	1	1	1	NT	NT	8	8		97	97
181					1	1	1	1	1/2	1/2	8	2		100	100
186					0	0	0	0	0	0	8	6		99	99
189	1	1	1	1									95		
190					5	5	5	5	5	5	100	10		95	95
193	-	-	+	-	-	-	-	-	-	-	++++	-	95	99	95
194					-	-	-	-	-	-	-	-			
195					2	2	2	2	2	2	6	6		80	70
197					-	-	-	-	-	-	Strong	-		90	90
204					1	1	1	1	1	1	8	1		95	90
206					1	1	1	1	1	1	8	1		100	60
209	1	1	2	1					NT	NT	NT	NT			
216	2	1	1	1									95		
227					-	-	-	-	-	-	8	-		98	98
229															
235	1	1	4	1									85		
238	1	1	2	1	1	1	1	1	1	1	8	2		98	60
245	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
252	1	1	1	1					1	1	6-8	4-6	85		70
260					NT	NT	NT	NT	NT	NT	NT	NT		30	30
262	1	1	1	1	1	1	1	1	1	1	8	4	100	100	100
268					1	1	1	1	1	1	6	1		92	86
284					1	1	1	1	1	1	8	6		98	98
292					1	1	1	1	1	1	6	1		85	50
293					0	0	2+	0	0	0	8+	6+		70	40
294					0	0	0	0	0	0	8	0		100	95
297					1	1	1	1	1	1	8	1		80	80
321					1	1	1	1	1	1	8	1		98	92
351															